← FDA DRUG APPROVALS

FDA ANDA · ANDA214092

CARBIDOPA AND LEVODOPA

Sponsor: SCIEGEN PHARMS

APPLICATION
ANDA214092
TYPE
ANDA
ORIGINAL APPROVAL
2021-05-07
LATEST ACTION
2021-05-07
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

CARBIDOPA AND LEVODOPAPrescription
CARBIDOPA 25MG, LEVODOPA 250MG · TABLET · ORAL
CARBIDOPA AND LEVODOPAPrescription
CARBIDOPA 10MG, LEVODOPA 100MG · TABLET · ORAL
CARBIDOPA AND LEVODOPAPrescription
CARBIDOPA 25MG, LEVODOPA 100MG · TABLET · ORAL

Approval history

2021-05-07UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →